WASHINGTON, DC-A new nucleotide analog has been passed by the US Food and Drug Administration (FDA) in an attempt to help the current list of anti-viral AIDS drugs.
Viread, manufactured by Gilead Sciences of Foster City, Calif., was created to help fight against the rapidly mutating virus that has managed to create a resistance to many current AIDS drugs. The once-a-day pill will be available by week's end. Side effects include moderate diarrhea, nausea, vomiting, and flatulence.
In clinical trials of the drug, AIDS patients were found to have significant reduction in the amount of HIV cells in their bloodstream.
Viread is also known as tenofovir disoproxil fumarate.
Information from www.sfgate.com
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.
Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski
June 26th 2025In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.